IDH1 and central nervous system cancer: The AB metrics were statistically significantly different from the FS metrics for almost all metrics and glioma subgroup, with the exception of IDH-wild-type in the amides range, and IDH-mutant_1p/19qret without AB/FS mismatch in the amides range (Table 3).